CNS Pharmaceuticals (CNSP) lists director Michal with no reported trades
Rhea-AI Filing Summary
CNS Pharmaceuticals, Inc. filed an initial statement of beneficial ownership on Form 3 for Fisher Michal, who is identified as a director of the company. The filing notes an attached Power of Attorney, authorizing representation in securities reporting matters. No specific transactions are reported.
Positive
- None.
Negative
- None.
Key Terms
Form 3, beneficial ownership, Power of Attorney
3 terms
Form 3 regulatory
"filed an initial statement of beneficial ownership on Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"filed an initial statement of beneficial ownership on Form 3"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Power of Attorney regulatory
"Exhibit 24 - Power of Attorney"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
FAQ
What does the CNSP Form 3 filing for Fisher Michal report?
The Form 3 for CNSP reports that Fisher Michal is a director of CNS Pharmaceuticals, Inc. It is an initial statement of beneficial ownership and does not list any specific securities transactions.
Is Fisher Michal a 10% owner of CNS Pharmaceuticals (CNSP)?
The Form 3 for CNSP indicates Fisher Michal is a director and not a 10% owner. The filing classifies their role only as director, without marking ten percent owner status.
Does the CNSP Form 3 show any stock trades by Fisher Michal?
The Form 3 for CNSP does not report any transactions. All transaction-related summary counts, including buys, sells, and derivative exercises, are shown as zero in the structured data.
What is the significance of the Power of Attorney in the CNSP Form 3?
The Form 3 for CNSP references an exhibit titled Power of Attorney. This typically authorizes another party to sign and submit securities filings on the insider’s behalf for administrative convenience.
Does the CNSP Form 3 mention a Rule 10b5-1 trading plan?
The Form 3 data for CNSP shows the Rule 10b5-1 plan indicator as null, meaning the record does not specify whether any plan applies, and no related footnote is provided.
AI-generated analysis. How Rhea-AI works. Not financial advice.
